Epigral’s Q1FY27 PAT Jumps 25% as Company Plans ₹600 Crore Capex for Epoxy Resin Expansion

Epigral’s Q1FY27 PAT Jumps 25% as Company Plans ₹600 Crore Capex for Epoxy Resin Expansion​

Ahmedabad, July 27, 2026: Epigral Limited, a leading integrated chemical manufacturer in India, announced financial results for the quarter ended June 30, 2026. The company reported a substantial growth of 25% in Profit After Tax (PAT) for Q1FY27 at ₹99 Crore, up from ₹79 Crore recorded in Q1FY26. Quarterly revenue also saw a rise of 15%, reaching ₹709 Crore compared to ₹615 Crore in the previous fiscal year's corresponding quarter.

The company continues its strategic expansion by approving entry into the Epoxy Resin and Formulations business, alongside setting up a Multi-Purpose Plant (MPP). This dual project carries an estimated capital expenditure (capex) investment of approximately ₹600 crore, with commercial commissioning for both plants anticipated in the second half of FY28.

Key Financial Performance Highlights​

Epigral demonstrated steady performance across several key metrics in Q1FY27:


The company’s operational performance also saw improvements, with absolute EBITDA growing by 10%. Furthermore, YoY sales volume increased by 5%, and overall plant utilization stood above 80%.

Strategic Expansion into Advanced Materials​

The strategic moves reflect Epigral's push toward greater integration within the advanced materials and specialty chemicals segment. The planned Epoxy Resin and Formulations facility is slated to have a production capacity of 1,25,000 Tonnes Per Annum (TPA). Concurrently, Epigral is establishing an MPP dedicated to downstream products derived from the Epichlorohydrin (ECH) and Chlorotoluenes value chains.

The move into Epoxy Resin addresses growing demand across various sectors, including construction, renewable energy, automotive, infrastructure, aerospace, marine structures, industrial flooring, and semiconductor applications. The Epoxy Resin material itself is vital for high-performance uses such as windmill blades, fiber reinforced polymers, and tile adhesives.

This strategic expansion benefits significantly from Epigral's existing operational structure. Key raw materials required for manufacturing the Epoxy Resin, including Epichlorohydrin (ECH) and Caustic Soda, are already produced within the company's integrated complex in Dahej. This internal sourcing ensures that over 50% of the raw material value for the proposed project will be met internally, reinforcing the company's backward integration advantage.

In line with its phased development plan, a pilot plant facility for Epoxy Resin and Formulations, alongside the MPP, is also being set up and is expected to be operational by Q2FY27. This pilot stage aims to validate product quality, optimize manufacturing processes, and secure customer approvals prior to commercial scale production.

Management Outlook and Commitment​

Maulik Patel, Chairman and Managing Director of Epigral Limited, commented on the results and future strategy. He noted that Epigral achieved steady growth in Q1FY27 despite macroeconomic volatility driven by geopolitical tensions and fluctuations in raw material and finished goods prices. By leveraging its diversified product mix, the company successfully navigated these headwinds to achieve 15% revenue growth and a 25% EBITDA margin.

Mr Patel stated that management maintains a positive outlook, supported by India's strong economic trajectory. The approvals for the Epoxy Resin plant and MPP are designed to enhance efficiency within Epigral's integrated manufacturing complex by utilizing internal raw materials. While the Epoxy Resin plant will target domestic and global demand in renewable energy and automotive sectors, the MPP is focused on rising domestic requirements for pharmaceutical and agrochemical intermediates and water treatment chemicals.

These investments underscore Epigral’s commitment to building an integrated manufacturing platform and diversifying its portfolio to generate long-term stakeholder value.

EPIGRAL Stock Price Movement​

Shares of Epigral Limited are shedding 0.82% as of 3:12 PM today, trading down to ₹1153.2 after registering a decline of ₹9.50 per share. The stock has seen significant activity in the live market, with over 600,722 shares traded so far this session.